Medical Device Market Access: How to Win Over the Value Analysis Committee

2026-07-13 · Caduvo Team

Market access for medical devices isn’t just about FDA clearance. Learn how hospital value analysis committees evaluate new products, the evidence they demand, and a realistic go-to-market sequence.

Your device has FDA clearance. The clinical data looks solid. But when your sales team walks into the hospital, they hit a wall: “We need to run this through Value Analysis.” That phrase can stall a product launch for months—or kill it.

Market access for medical devices is more than a regulatory milestone. It’s the chain of decisions that gets a product purchased, stocked, and used. At the end of that chain sits the value analysis committee (VAC). If you don’t understand what these committees ask for, you’re building a launch plan on hope, not evidence.

What Medical Device Market Access Actually Means

Medical device market access is the process that turns a legally marketable device into one that gets paid for and adopted by hospitals. It has four interlocking parts: regulatory clearance, coding, coverage, and payment. Each one must be in place before a VAC will even put you on the agenda.

A device with an FDA product code but no assigned billing code is invisible to a hospital’s purchasing system. A device with a code but no payer coverage policy gets used once and then rejected. And a device with coverage but a payment rate that doesn’t cover costs gets pulled off the shelf.

Medical device reimbursement is the backbone, but market access goes further: it includes the internal hospital review that decides whether to stock your product at all. That review is run by the VAC.

The Value Analysis Committee: Who’s in the Room and What They Want

A value analysis committee is a cross-functional hospital group that evaluates new products for purchase. Membership typically includes:

• Supply chain or materials management
• Clinical representation (nursing, physician champions, sometimes pharmacy)
• Finance or administration
• Risk management or infection control
• Value analysis specialists (larger systems may have dedicated staff)

VACs look at every new request through three lenses:

• Clinical value: Does this product improve outcomes, reduce complications, or shorten length of stay compared to what we use today? They want comparative data, not just FDA clearance.
• Economic impact: What’s the total cost of adoption, factoring in purchase price, utilization changes, training, and any downstream savings? A lower unit price doesn’t guarantee a win if supply chain has to stock new SKUs or reprocessing adds cost.
• Operational fit: Can the hospital’s existing workflows, sterilization processes, and IT systems accommodate this device? A product that requires a new instrument tray or disrupts OR turnover time creates hidden costs.

The committee’s single question: “Why should we switch?” Answering it takes a specific evidence package.

The Evidence Package That Gets a VAC’s Attention

Too many MedTech teams lead with a features-and-benefits pitch. VACs are looking for something else. Here’s what you need.

Clinical evidence

• Peer-reviewed data, ideally with a comparator arm. A single-arm study showing 95% success means less than a randomized trial showing 15% fewer reoperations than the incumbent.
• Real-world data from your first sites, if available. Registries and observational studies carry weight, especially if they show consistent results outside academic centers.
• For breakthrough device designation products, early evidence can sometimes be enough, but you’ll still need a postmarket data plan.

Economic evidence

• A budget impact model tailored to the hospital’s payer mix and volume. Don’t hand over a one-size-fits-all spreadsheet. Show them their numbers.
• Clarity on the reimbursement pathway. What HCPCS or CPT code will the hospital use? Is there a Medicare national or local coverage determination that supports payment? Can you document how commercial payers are handling it?
• If the device shifts care from inpatient to outpatient, model the facility payment impact. That’s often a stronger lever than clinical appeal alone.

Operational readiness

• A one-page implementation summary: required training hours, sterile processing compatibility, shelf-life, and any EMR integration needs.
• A named contact for in-service support during the first 30 days. VACs want to know who shows up, not just what you’re shipping.

Sequencing Your Medical Device Go to Market Strategy

A realistic medical device go to market strategy builds the infrastructure before the VAC presentation. Trying to do it backwards—pitch first, figure out coding later—is how products get blacklisted.

Phase 1: Pre-launch (12–18 months before commercial activity)

• Lock down the FDA pathway and clearance. Know your product code and classification.
• Secure a billing code. For physician-office procedures, that’s usually CPT. For hospital outpatient, DME, or supplies, it’s HCPCS Level II. If no existing code fits, start the application 18–24 months ahead of launch.
• Research payer coverage. Use the Medicare Coverage Database to identify favorable LCDs and any restrictive NCDs. Begin early dialogue with private payers that cover your target population.
• Build the clinical evidence package. Plan postmarket studies now, not after the VAC asks for them.

Phase 2: Launch readiness (6–12 months before first sale)

• Identify 3–5 VACs at target accounts and request their submission requirements. Some use online portals; others want a 20-page dossier.
• Run a mock VAC presentation with a clinician and a supply chain executive as reviewers. The questions you get will be the ones that matter.
• Prepare a budget impact model that lets you plug in a specific hospital’s volume, payer mix, and current practice patterns.

Phase 3: Post-launch (first 12 months)

• Track every VAC outcome: approved, approved with conditions, tabled, rejected. That data tells you where your evidence needs strengthening.
• Gather real-world outcomes from early adopters to feed back into the VAC evidence package for the next wave of hospitals.

During all three phases, having a clear reimbursement map matters. Platforms that pull coding, coverage, and payment data into a single view—like Caduvo’s reimbursement-intelligence tools—can compress the research phase from weeks to hours, but the real work still sits with the commercial team: translating that intelligence into a case the VAC will believe.

Short-Actionable Takeaways

• Start VAC preparation at least 9 months before you plan to sell. Waiting until you have a purchase order is too late.
• Build one economic model, but customize it for each hospital’s payer mix, volume, and current practice. Generic models get ignored.
• Never walk into a VAC without confirming your billing code and at least one positive coverage policy. If you can’t show how the hospital gets paid, the conversation stops.
• Ask a VAC coordinator what evidence format they want. Some systems require a structured value analysis form; others accept a dossier. Follow their process, not yours.
• Track every committee decision. A pattern of “tabled for more data” means your clinical or economic evidence isn’t hitting the mark—fix that before you approach the next account.